PRINCETON, N.J. & REHOVOT, Israel -- (Business Wire)
Rosetta Genomics Ltd. (NASDAQ:ROSG), a leading developer and provider of
microRNA-based and other molecular diagnostics, announces that company
management will participate at the 2015 Inaugural “From Bench to
Bedside” Healthcare Conference hosted by Cantor Fitzgerald. The
conference will take place at Le Parker Meridien Hotel in New York City
on Wednesday, July 8th. Ken Berlin, President and Chief Executive
Officer of Rosetta Genomics, will deliver a corporate overview at 2:00
p.m. Eastern time.
Mr. Berlin’s presentation will be webcast live and can be accessed by
visiting the investor section of the company’s website at www.rosettagenomics.com.
The webcast will be archived for a period of 90 days following the live
webcast.
About Rosetta Genomics
Rosetta develops and commercializes a full range of microRNA-based and
other molecular diagnostics. Rosetta’s integrative research platform
combining bioinformatics and state-of-the-art laboratory processes has
led to the discovery of hundreds of biologically validated novel human
microRNAs. Building on its strong patent position and proprietary
platform technologies, Rosetta is working on the application of these
technologies in the development and commercialization of a full range of
microRNA-based diagnostic tools. Through the acquisition of
PersonalizeDx, the Company offers core FISH, IHC and PCR-based testing
capabilities and partnerships in oncology and urology that provide
additional content and platforms that complement the Rosetta offerings.
Rosetta’s and PersonalizeDx’s cancer testing services are commercially
available through the Philadelphia, PA- and Lake Forest, CA-based
CAP-accredited, CLIA-certified labs, respectively. For more information
visit www.rosettagenomics.com.
Forward-Looking Statement Disclaimer
Various statements in this release concerning Rosetta’s future
expectations, plans and prospects constitute forward-looking statements
for the purposes of the safe harbor provisions under The Private
Securities Litigation Reform Act of 1995. Actual results may differ
materially from those indicated by these forward-looking statements as a
result of various important factors, including those risks more fully
discussed in the "Risk Factors" section of Rosetta’s Annual Report on
Form 20-F for the year ended December 31, 2014 as filed with the SEC. In
addition, any forward-looking statements represent Rosetta’s views only
as of the date of this release and should not be relied upon as
representing its views as of any subsequent date. Rosetta does not
assume any obligation to update any forward-looking statements unless
required by law.
View source version on businesswire.com: http://www.businesswire.com/news/home/20150701005053/en/
Contacts:
Rosetta Genomics
Ken Berlin, President & CEO
(609) 419-9003
investors@rosettagenomics.com
or
Investor:
LHA
Anne
Marie Fields
(212) 838-3777
afields@lhai.com
or
Bruce
Voss
(310) 691-7100
bvoss@lhai.com
Source: Rosetta Genomics Ltd.
© 2024 Canjex Publishing Ltd. All rights reserved.